(Q21957029)

English

Inflammatory bowel disease: clinical aspects and established and evolving therapies

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

Inflammatory bowel disease: clinical aspects and established and evolving therapies (English)

0 references

inflammatory bowel diseases

0 references

William Jeffery Sandborn

2

object named as

William J Sandborn

author given names

William J

author last names

Sandborn

1 reference

PubMed publication ID

7 February 2023

author name string

Daniel C Baumgart

1

author given names

Daniel C

author last names

Baumgart

1 reference

PubMed publication ID

7 February 2023

language of work or name

0 references

publication date

May 2007

0 references

1 reference

369

0 references

9573

0 references

1641-1657

0 references

Inflammatory bowel disease: cause and immunobiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical practice. Acute infectious diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the management of inflammatory bowel disease in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Course of ulcerative colitis: analysis of changes in disease activity over years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in extent of ulcerative colitis: a study on the course and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily, high-concentration MMX mesalamine in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cortisone in ulcerative colitis; final report on a therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive intravenous regimen for severe attacks of ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised controlled trial of azathioprine withdrawal in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Review article: systemic and topical steroids in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute surgical emergencies in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Current concepts and controversies in surgery for IBD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of Crohn's disease in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease activity courses in a regional cohort of Crohn's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term evolution of disease behavior of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Low dose steroids and clinical relapse in Crohn's disease: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of an intravenous steroid regimen in the treatment of acute Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Double blind, placebo controlled trial of metronidazole in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The effectiveness of budesonide therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

RDP58 is a novel and potentially effective oral therapy for ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

AGA technical review on perianal Crohn’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Onercept for Moderate-to-Severe Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-interleukin-12 antibody for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Natalizumab for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sargramostim for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A preliminary study of growth hormone therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Fertility and pregnancy in the patient with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer risk in patients with inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960751-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(07)60751-X

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q21957029&oldid=1947633854"